Gland Pharma Management Guidance Tracker

Management expects consolidated revenue to grow in mid-teens for the full year, driven by new product launches and market expansion.

Management reaffirmed mid-teens percentage revenue growth for FY26, driven by new launches and Senexi improvement.

Management expects base business to grow 12-13% in FY27, with potential upside from CDMO contracts and liraglutide US approval.

Synexi's Q3 revenue of €50 million sets a baseline for annualized revenue of ~€200 million, with potential quarterly fluctuations.

Management guided for 12-13% constant currency revenue growth in FY27, driven by new product launches, CDMO ramp-up, and SenXi improvement.

Synergia is committed to delivering positive EBITDA in Q3 FY26, after a lower Q2 due to summer shutdown.

Senexi is expected to achieve EBITDA breakeven in Q3 FY26, supported by €50M quarterly revenue target.

Base business EBITDA margin expected to be around 35% for FY27, supported by operating leverage and cost efficiencies.

SenXi targets mid-teen EBITDA margin in the medium term, with FY27 expected to reach high single-digit EBITDA margin.

The new 100M unit line will be ready for commercialization by March-April 2026, with FAT completed by September 2025.

Cartridge fill-finish capacity to increase from 40M to 140M units by mid-FY27, targeting GLP-1 and insulin.

Planned capex of ~₹2,000 crore over next 5 years for brownfield expansions, BFS line, and CDMO contracts, with FY27 capex >₹400 crore.

Capital expenditure of approximately ₹500 crore planned for FY27, part of ₹2,000 crore investment over five years for capacity expansion.

Management expects to commercialize around 20 million pens/cartridges in FY27 from the expanded capacity.

Company targets 15% organic CAGR over 5 years, excluding inorganic contributions, driven by capacity expansion and CDMO wins.

Biologic CDMO capacity to expand from 8k to 23k liters in the next phase to support biosimilar and biologic fill-finish.